Kymera Therapeutics (KYMR) revenue

Revenue · fiscal 2025
$39.21M

Kymera Therapeutics (KYMR) reported revenue of $39.21M in fiscal 2025 (the year ended December 31, 2025). That is 16.7% lower than the $47.07M of fiscal 2024. Figures as of 18 Nov 2026, 10:50 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$39.21M
Change on fiscal 2024
−16.7%
Growth, 5 years
+2.9% a year
Highest on record
$78.59Mfiscal 2023
Lowest on record
$2.93Mfiscal 2019
Fiscal years on record
72019–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Kymera Therapeutics revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 2.9% a year. Across the 7 fiscal years on record (2019–2025), the highest was $78.59M in fiscal 2023 and the lowest $2.93M in fiscal 2019.

History · 7 fiscal years

Revenue by fiscal year

Kymera Therapeutics revenue, year by year

Kymera Therapeutics (KYMR) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$39.21M 16.7% down
2024$47.07M 40.1% down
2023$78.59M 67.8% up
2022$46.83M 35.7% down
2021$72.83M 114.0% up
2020$34.03M 1,060.0% up
2019$2.93M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Kymera Therapeutics and comparable companies
CompanyRevenueFiscal year
Fresenius Medical Care FMS€19.63B2025
Kymera Therapeutics KYMR$39.21M2025
DaVita DVA$13.64B2025
Halozyme Therapeutics HALO$1.40B2025
Universal Health Services UHS$17.36B2025
Repligen RGEN$738.26M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KYMR

Kymera Therapeutics, figure by figure

Kymera Therapeutics (KYMR) overview: price, valuation and scorecardAll health care companies by market value

Kymera Therapeutics revenue: questions and answers

What is Kymera Therapeutics's revenue?

Kymera Therapeutics (KYMR) reported revenue of $39.21M in fiscal 2025 (the year ended December 31, 2025). That is 16.7% lower than the $47.07M of fiscal 2024.

What is the growth rate of Kymera Therapeutics's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 2.9% a year.

What are the highest and lowest revenue figures on record for Kymera Therapeutics?

Across the 7 fiscal years on record (2019–2025), the highest was $78.59M in fiscal 2023 and the lowest $2.93M in fiscal 2019.

How is Kymera Therapeutics's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Kymera Therapeutics it is on record here for 7 fiscal years, 2019 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Kymera Therapeutics (KYMR) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/KYMR/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.